Presentation

Company Profile
Navamedic is a Norwegian pharma company headquartered in Oslo with a footprint in Northern Europe. Its product portfolio consists of Rx and OTC pharmaceuticals and other healthcare products registered as medical nutrition and medical devices. food supplements or cosmetics. Navamedic is present in all Nordic countries, the Baltics and Benelux, and has specific products even in European countries like the UK and Greece. Navamedic has a high-potential pipeline and an ambitious growth strategy built on strong M&A capabilities.

Recent highlights
The company delivered a very strong Q2 report with revenues of NOK 66m (up 56.7% y/y. The gross margin was 39.3%, up from 34.8% in Q2 2020, and an EBITDA of NOK 4.3m (-2.1m in Q2 20). Navamedic saw strong demand for the products Mysimba, Alflorex and ThermaCare and also saw general good underlying demand for several other products. Navamedic entered into a long-term distribution agreement for PrecisionBiotics Zenflore in the Nordics, an additional gastro product. In June, Navamedic also secured its first tender for the entire Norwegian market for four major antibiotics.

Outlook
Navamedic has a financial target to grow 20% annually from 2021 with a mid-to-long-term ambition of building a NOK 500m company with a gross margin of 40% and an EBITDA margin of 15%.